Financials

  • Market Capitalization 487.04 M
  • Employee 48
  • Founded 2020
  • CEO N/A
  • Website www.evommune.com
  • Headquarter Delaware, United States
  • FIGI BBG00Y79N887
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-1.53
Relación precio/flujo de caja
8.08

Related tickers

#NombrePrecio24h %7d %1M %1A %CapitalizaciónÚltimos 7 días
2919
CCCC
C4 Therapeutics, Inc. - Common Stock
4.10 USD-3.30%+3.02%+18.84%+62.06%504.40 M USD
2931
PRLD
Prelude Therapeutics Incorporated - Common Stock
5.84 USD-7.89%-11.38%+25.86%+352.71%466.05 M USD
2948
PRTA
Prothena Corporation plc - Ordinary Shares
9.31 USD+2.42%+0.32%+7.75%+12.58%477.95 M USD
2951
RLMD
Relmada Therapeutics, Inc. - Common Stock
4.41 USD-2.43%-4.75%-15.68%+431.33%470.41 M USD